# Spectral AI, Inc.

Type: Company (MDAI)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/spectral-ai-inc
Canonical HTML page: https://getbiobrief.com/entity/spectral-ai-inc

## Timeline

- **2026-03-24**: Earnings Release — Official announcement of Q4 and FY2025 results and introduction of 2026 guidance.
- **2026-01-01**: Guidance Period Start — Commencement of the 2026 fiscal year covered by the new revenue outlook.
- **2025-12-31**: Fiscal Year End — Spectral AI closes the year with $15.4M in cash and $19.7M in R&D revenue.

## Recent coverage (1 stories)

### Spectral AI Reports $19.7M FY2025 Revenue, Sets 2026 Growth Guidance
2026-03-24 20:47:30 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Spectral AI reported full-year 2025 R&D revenue of $19.7 million, driven by its DeepView AI-driven wound diagnostic platform. The company ended the year with $15.4 million in cash and provided its first revenue outlook for 2026, signaling a transition toward commercial scale.
Full story: https://getbiobrief.com/story/spectral-ai-fy2025-earnings-2026-guidance

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.